Who is sponsoring NCT02634853?

NCT02634853 is sponsored by Mimetogen Pharmaceuticals USA, Inc..

What drugs are being tested in NCT02634853?

Interventions in NCT02634853: 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution.

What condition does NCT02634853 study?

NCT02634853 studies Keratoconjunctivitis Sicca.

Is NCT02634853 still recruiting?

NCT02634853 is currently completed. Last updated 13 August 2019.

Last reviewed 2019-08-13 · How we verify

NCT02634853

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Completed Phase 3 Last updated 13 August 2019

What this trial tests

Phase 3 trial testing 1% Tavilermide Ophthalmic Solution in Keratoconjunctivitis Sicca in 429 participants. Completed in 1 March 2017.

Timeline

1 December 2015

Primary endpoint
1 February 2017

1 March 2017

Quick facts

Lead sponsor	Mimetogen Pharmaceuticals USA, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	429
Start date	1 December 2015
Primary completion	1 February 2017
Estimated completion	1 March 2017
Sites	2 locations across United States

Drugs / interventions tested

1% Tavilermide Ophthalmic Solution — full drug profile →
Placebo Ophthalmic Solution — full drug profile →

Conditions studied

Keratoconjunctivitis Sicca — all drugs for Keratoconjunctivitis Sicca →

Sponsor

Mimetogen Pharmaceuticals USA, Inc. — full company profile →

Who can join

18 and older, any sex, with Keratoconjunctivitis Sicca. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Corneal Fluorescein Staining
Time frame: Day 57
Ocular Discomfort
Time frame: Day 57

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mimetogen Pharmaceuticals USA, Inc. trials

Trials by the same sponsor.

NCT05848128 — Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye · Phase 3 · completed
NCT03925727 — Tavilermide Ophthalmic Solution for the Treatment of Dry Eye · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02634853 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mimetogen Pharmaceuticals USA, Inc.
Last refreshed: 13 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02634853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing